Loading...
Please wait, while we are loading the content...
Similar Documents
Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks
| Content Provider | MDPI |
|---|---|
| Author | Maximilian, Töllner Florian, Kälble Caner, Süsal Speer, Claudius Schaier, Matthias Nusshag, Christian Buylaert, Mirabel Reichel, Paula Grenz, Julia Zeier, Martin Schnitzler, Paul Morath, Christian Klein, Katrin Benning, Louise |
| Copyright Year | 2021 |
| Description | It has been demonstrated that patients on hemo- or peritoneal dialysis are particularly susceptible to SARS-CoV-2 infection and impaired seroconversion compared to healthy controls. Follow-up data on vaccination response in dialysis patients is limited but is greatly needed to individualize and guide (booster) vaccination strategies. In this prospective, multicenter study we measured anti-spike S1 and neutralizing antibodies in 124 hemodialysis patients, 41 peritoneal dialysis patients, and 20 age- and sex-matched healthy controls over 12 weeks after homologous BNT162b2 vaccination. Compared to healthy controls, both hemodialysis and peritoneal dialysis patients had lower anti-S1 IgG antibodies (median (IQR) 7.0 (2.8–24.3) and 21.8 (5.8–103.9) versus 134.9 (23.8–283.6), respectively; p < 0.001 and p < 0.05) and a reduced SARS-CoV-2 spike protein–ACE2 binding inhibition caused by vaccine-induced antibodies (median (IQR) 56% (40–81) and 77% (52–89) versus 96% (90–98), respectively; p < 0.001 and p < 0.01) three weeks after the second vaccination. Twelve weeks after the second vaccination, the spike protein–ACE2 binding inhibition significantly decreased to a median (IQR) of 45% (31–60) in hemodialysis patients and 55% (36–78) in peritoneal dialysis patients, respectively (p < 0.001 and p < 0.05). Peritoneal dialysis patients mounted higher antibody levels compared with hemodialysis patients at all time points during the 12-week follow-up. Individual booster vaccinations in high-risk individuals without seroconversion or rapidly waning neutralizing antibody levels are required and further data on the neutralization of emerging variants of concern in these patients are urgently needed. |
| Starting Page | 1130 |
| e-ISSN | 2076393X |
| DOI | 10.3390/vaccines9101130 |
| Journal | Vaccines |
| Issue Number | 10 |
| Volume Number | 9 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2021-10-04 |
| Access Restriction | Open |
| Subject Keyword | Vaccines Urology and Nephrology Covid-19 Covid-19 Vaccination Hemodialysis Peritoneal Dialysis Humoral Response Bnt162b2 Vaccination Strategy Sars-cov-2 |
| Content Type | Text |
| Resource Type | Article |
